BBOT (BridgeBio Oncology Therapeutics) ROE % Adjusted to Book Value: -22.28% (As of Mar. 2026)


BBOT BridgeBio Oncology Therapeutics Inc BBOT
12 GF Score
Price $8.40
View Full Analysis

What is BridgeBio Oncology Therapeutics ROE % Adjusted to Book Value?

BridgeBio Oncology Therapeutics BBOT +3.70% 12 ROE % Adjusted to Book Value is -22.28% as of Mar. 2026. GuruFocus rates BBOT with a GF Score™ of 12/100.

BridgeBio Oncology Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -43.00%. BridgeBio Oncology Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 1.93. BridgeBio Oncology Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -22.28%.

BridgeBio Oncology Therapeutics ROE % Adjusted to Book Value Related Terms

BridgeBio Oncology Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for BridgeBio Oncology Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Oncology Therapeutics ROE % Adjusted to Book Value Chart

BridgeBio Oncology Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 -47.27

BridgeBio Oncology Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -79.77 -14.83 -22.28

BBOT vs FTH, MNPR, MDXG: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, BridgeBio Oncology Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Oncology Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Oncology Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BridgeBio Oncology Therapeutics's ROE % Adjusted to Book Value falls into.


BBOT
12GF Score
BridgeBio Oncology Therapeutics Inc BBOT
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Oncology Therapeutics ROE % Adjusted to Book Value Calculation

BridgeBio Oncology Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-115.33% / 2.44
=-47.27%

BridgeBio Oncology Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-43.00% / 1.93
=-22.28%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -22.28% mean?
BridgeBio Oncology Therapeutics (BBOT) has a ROE % Adjusted to Book Value of -22.28% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BridgeBio Oncology Therapeutics and its competitors.
Is BridgeBio Oncology Therapeutics' ROE % Adjusted to Book Value too high?
BridgeBio Oncology Therapeutics' current ROE % Adjusted to Book Value is -22.28%. Overall, BridgeBio Oncology Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Oncology Therapeutics' ROE % Adjusted to Book Value compare to FTH and MNPR?
BridgeBio Oncology Therapeutics' ROE % Adjusted to Book Value of -22.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BridgeBio Oncology Therapeutics and its competitors. BridgeBio Oncology Therapeutics's current ROE % Adjusted to Book Value is -22.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Oncology Therapeutics stock overvalued right now?
BridgeBio Oncology Therapeutics (BBOT) has a current ROE % Adjusted to Book Value of -22.28%. The current ROE % Adjusted to Book Value is -22.28%. BridgeBio Oncology Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BridgeBio Oncology Therapeutics (BBOT), the current ROE % Adjusted to Book Value is -22.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BridgeBio Oncology Therapeutics Business Description

Address 256 East Grand Avenue, Suite 104, South San Francisco, CA, USA, 94080
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
12GF Score

Get the complete analysis for BBOT

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price